Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose oral MMX mesalamine (Mezavant) vs delayed-release mesalamine (Asacol) for induction of remission in mild to moderate ulcerative colitis
KCT0009194Phase 4Not yet recruiting
- Sponsor
- Incheon St. Mary's Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Incheon St. Mary's Hospital. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on KCT0009194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009194.